BiotechTube

ibandronate [Bonviva/Boniva] + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post-Menopausal Osteopenia

Conditions

Post-Menopausal Osteopenia

Trial Timeline

— → Sep 1, 2010

NCT ID
NCT00545207

About ibandronate [Bonviva/Boniva] + Placebo

ibandronate [Bonviva/Boniva] + Placebo is a phase 3 stage product being developed by Roche for Post-Menopausal Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00545207. Target conditions include Post-Menopausal Osteopenia.

What happened to similar drugs?

8 of 14 similar drugs in Post-Menopausal Osteopenia were approved

Approved (8) Terminated (0) Active (6)
✅raloxifene + PlaceboEli LillyApproved
🔄teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
✅Teriparatide + Zoledronic AcidEli LillyApproved
🔄teriparatideEli LillyPhase 3
✅Raloxifene + Raloxifene + PlaceboEli LillyApproved
✅TeriparatideEli LillyApproved
🔄teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00545207Phase 3Completed

Competing Products

19 competing products in Post-Menopausal Osteopenia

See all competitors
ProductCompanyStageHype Score
raloxifene + PlaceboEli LillyApproved
43
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
Teriparatide + Zoledronic AcidEli LillyApproved
43
teriparatideEli LillyPhase 3
40
Raloxifene + Raloxifene + PlaceboEli LillyApproved
43
TeriparatideEli LillyApproved
43
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
MK0429MerckPhase 2
35
PTH134 + Placebo + ForsteoNovartisPhase 1
29
Placebo + Zoledronic acidNovartisPhase 3
40
zoledronic acid + Any oral bisphosphonates marketed in CanadaNovartisPre-clinical
26
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + AlendronateRocheApproved
43
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
43
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
43
Placebo + ibandronate [Bonviva/Boniva]RocheApproved
43
IbandronateRochePhase 3
40
romosozumab HCP administration with PFSAmgenPhase 3
40
Romosozumab + Alendronate (Fosamax) + Placebo Romosozumab + Placebo AlendronateAmgenPhase 2
42
BAY3427080 + Placebo (for BAY3427080)BayerPhase 1/2
29